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ABSTRACT 
Methocinnamox (MCAM), a mu opioid receptor antagonist with a long duration of action, 
attenuates heroin self-administration in rhesus monkeys, suggesting it could be an 
effective treatment for opioid use disorder (OUD). This study examined effects of acute 
and repeated MCAM administration on self-administration of the high-efficacy mu opioid 
receptor agonist fentanyl and characterized MCAM pharmacokinetics. Four rhesus 
monkeys self-administered i.v. infusions of fentanyl (0.00032 mg/kg/infusion) or cocaine 
(0.032 mg/kg/infusion). MCAM (0.1-0.32 mg/kg) or the opioid receptor antagonist 
naltrexone (0.001-0.032 mg/kg) was injected prior to test sessions to evaluate acute 
effects. On a separate occasion, 0.32 mg/kg MCAM was injected every 12 days for 5 total 
injections to evaluate the effectiveness of repeated treatment. Following acute injection, 
MCAM and naltrexone decreased fentanyl self-administration on the day of treatment, 
with attenuation lasting for up to 2 weeks after the larger MCAM dose and <1 day after 
naltrexone. Repeated MCAM administration decreased fentanyl self-administration for 
more than 2 months without altering cocaine self-administration. MCAM plasma 
concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7-199.8 
min, and decreased markedly 1 day after injection. MCAM selectively reduces opioid self-
administration and remains effective with repeated administration. Moreover, MCAM was 
effective at times when plasma levels were very low, suggesting that pharmacodynamic 
(i.e., pseudoirreversible binding to mu opioid receptors) and not pharmacokinetic factors 
play a significant role in its long-lasting effects. Taken together with previous studies, 
these data indicate that MCAM could be a safe, effective, and long-acting treatment for 
OUD.  
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INTRODUCTION 
The opioid crisis continues despite the availability of medications that are effective 
in some patients [1]. The most common evidence-based treatment for opioid use disorder 
(OUD) includes medication-assisted therapy; currently approved medications comprise 
the full mu opioid receptor agonist methadone, the partial agonist buprenorphine, and the 
antagonist naltrexone. While these medications are effective, each has limitations. For 
example, although agonists such as methadone and buprenorphine replace abused 
opioids and mitigate risks associated with illicit drug use, treatment with mu opioid 
receptor agonists promotes physical dependence, carries significant potential for 
diversion, and increases the risk of dangerous interactions with other drugs such as 
alcohol and benzodiazepines [e.g., 1,2]. Mu opioid receptor antagonists such as 
naltrexone avoid many of adverse effects associated with agonists; however, naltrexone 
binds to opioid receptors in a competitive, reversible manner. Therefore, antagonist 
effects can be surmounted by taking large doses of an agonist. Moreover, naltrexone has 
a very short duration of action, requiring daily administration (e.g., Revia®), which can 
result in low treatment adherence. Although an extended release formulation of 
naltrexone (Vivitrol®) is available, the surmountability limitation remains, and low 
treatment adherence and limited effectiveness continue to be significant challenges [4,5]. 
The severity of the opioid crisis taken together with limitations of currently available 
treatments underscores the urgent need to discover and develop additional safe and 
effective treatments for OUD [6].  
Methocinnamox (MCAM) is an opioid receptor antagonist that binds to but does 
not dissociate from the mu opioid receptor, rendering the receptor unavailable to other 
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ligands. Binding to mu opioid receptors in this manner suggests an irreversible interaction 
between MCAM and the receptor; however, unlike prototypical irreversible ligands such 
as β-funaltrexamine [7], MCAM does not form a covalent bond with the receptor and is, 
therefore, considered to be pseudoirreversible. Consistent with its pseudoirreversible 
antagonist properties, MCAM attenuates effects of mu opioid receptor agonists such as 
morphine in rodents, with effects persisting for days or weeks following a single 
administration [8,9,10]. MCAM also blocks the reinforcing and ventilatory-depressant 
effects of heroin and reduces choice of the mu opioid receptor agonist remifentanil over 
food in rhesus monkeys [11,12]. Effects of MCAM in monkeys also were remarkably long 
lasting, with a single injection of MCAM blocking effects of heroin for up to 2 weeks. 
Moreover, MCAM was effective at doses that did not decrease responding for food or 
alter physiological parameters such as heart rate, blood pressure, and body temperature 
[12]. Because MCAM has no pharmacological efficacy at mu opioid receptors, it would be 
expected to retain many benefits of naltrexone for treating OUD (e.g., no abuse potential, 
ventilatory depression, or adverse interactions with drugs that decrease ventilation) with 
the added benefit of being long acting and insurmountable as long as enough MCAM is 
given to occupy a sufficiently large number of mu opioid receptors. Long-term, 
insurmountable blockade of mu opioid receptors would have the advantage of increasing 
treatment compliance by reducing the frequency of medication administration and 
mitigating overdose risk insofar as the antagonist effects of MCAM could not be overcome 
by taking large doses of opioids. 
The current study extends this work by evaluating MCAM for its capacity to 
attenuate the reinforcing effects of the potent and high-efficacy mu opioid receptor agonist 
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fentanyl, which has contributed to a dramatic increase in mortality associated with opioid 
abuse [13]. Although previous studies demonstrated that MCAM selectively reduces 
opioid self-administration, it is important to know whether effects of MCAM are sustained 
with repeated treatment and whether extended treatment with MCAM results in long-term 
changes that might have important consequences. This study had the following three 
primary goals: 1) characterize effects (duration and selectivity) of acute treatment with 
MCAM on fentanyl self-administration; 2) evaluate effectiveness of repeated treatment 
with MCAM on fentanyl self-administration; and 3) examine MCAM in plasma in order to 
relate its pharmacokinetic profile to its behavioral effects. 
Monkeys were allowed to self-administer fentanyl, and, occasionally, cocaine was 
substituted for fentanyl to test for the selectivity of antagonism and to determine whether 
antagonism by MCAM was the result of blockade of mu opioid receptors or  some other 
nonselective effect, such as a generalized reduction in operant behavior, which is an 
important consideration for evaluating candidate medications for substance use disorders 
[14]. Moreover, given that MCAM was expected to decrease responding for fentanyl for 
an extended duration, responding for cocaine would confirm that the i.v. catheter was 
patent and the monkey would continue working for an i.v. infusion of drug. In addition, 
effects of MCAM were compared with those of naltrexone, the only mu opioid receptor 
antagonist currently approved in the US to treat OUD. It was hypothesized that both 
MCAM and naltrexone would attenuate fentanyl, but not cocaine, self-administration, and 
that antagonism by MCAM would be much longer lasting than antagonism by naltrexone, 
consistent with the persistent effects of MCAM at mu opioid receptors in previous studies 
[11,12]. Given that long-term blockade of mu opioid receptors might be expected to 
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perturb the endogenous opioid system, effects of naltrexone were re-determined 
periodically throughout the study to assess potential changes in effects (e.g., potency) of 
drugs acting at opioid receptors. 
 
MATERIALS AND METHODS 
Subjects. Eight adult rhesus monkeys, 7 males and 1 female, were housed 
individually in stainless steel cages in colony rooms maintained under a 14/10-hr 
light/dark cycle. Chow (High Protein Monkey Diet; Harlan Teklad, Madison, WI, USA), 
fresh fruit, peanuts, and treats were provided daily in amounts that maintained healthy 
sex- and age-appropriate weights, and water was continuously available in the home 
cage. Experiments were conducted in accordance with guidelines set forth by the Guide 
for the Care and Use of Laboratory Animals (8th edition; 2011) and protocols were 
approved by the University of Texas Health Science Center at San Antonio Institutional 
Animal Care and Use Committee. 
Surgery. Catheters were placed in monkeys participating in the self-administration 
experiment. After monkeys were sedated (10 mg/kg ketamine), anesthesia was 
maintained under 2 l/min oxygen and isoflurane. A 5-fr polyurethane catheter (Access 
Technologies, Skokie, IL, USA) was inserted and secured into a vein (e.g., jugular or 
femoral), tunneled subcutaneously (s.c.) to the mid-scapular region, and attached to a 
s.c. access port (Access Technologies). Meloxicam and Penicillin B&G were given 
postoperatively; ports and catheters were flushed daily with heparinized sterile saline to 
maintain catheter patency.  
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Apparatus. During sessions, monkeys were seated in chairs (Primate Products 
Inc., Immokalee, FL, USA). Monkeys participating in the self-administration experiment 
were positioned in light- and sound-attenuating chambers facing stainless-steel 
instrument panels with two horizontally aligned levers arranged below translucent disks 
that could be illuminated green or red. Infusions were delivered intravenously (i.v.) 
through the s.c. access port via a Huber point needle connected by a catheter extension 
to a syringe located in a syringe pump (Med Associates, St. Albans, VT, USA) [12,15]. 
Drug self-administration procedure. Four monkeys (3 males and 1 female) 
participated in the self-administration experiment; sessions were conducted once daily 
[12,15]. After monkeys were seated in chairs, weighed, and positioned in operant 
condition chambers, their ports and catheters were flushed with sterile 0.9% saline 
solution. Syringes and extension sets containing the solution available for self-
administration were connected to the Huber needle, and pumps were activated for 15 sec 
to fill the port and catheter with that solution. The session began with illumination of a red 
light over one lever (active) for 5 sec; a non-contingent infusion was delivered of the unit 
dose of drug available for self-administration in that session. Thereafter, the green light 
over the active lever was illuminated, signaling a response period, during which 30 
consecutive responses on the active lever turned off the green light, turned on the red 
light for 5 sec, turned on the syringe pump until the unit dose of drug was delivered, and 
initiated a 180-sec timeout. During timeouts, all lights were off and responding had no 
programmed consequence. At the end of the timeout, the green light over the active lever 
was illuminated, signaling another response period. Responses on the other lever 
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(inactive) reset the response counter on the active lever but otherwise had no scheduled 
consequence. Sessions ended after 90 min, inclusive of response periods and timeouts.  
Effects of acute naltrexone administration. Effects of naltrexone were 
determined while 0.00032 mg/kg/infusion fentanyl was available for self-administration; 
this unit dose of fentanyl is at or near the peak of the dose-effect curve for self-
administration [e.g., 16,17] and maintains levels of responding comparable to the unit 
dose of heroin used in the previous study with MCAM [12]. Monkeys received a s.c. 
injection 15 min prior to each session, with saline given prior to baseline sessions and 
naltrexone given prior to test sessions. Initially, baseline sessions occurred until the 
number of infusions obtained in each of 3 consecutive sessions did not vary by more than 
± 20% of the mean of those sessions; a dose of naltrexone was injected prior to the 
following (test) session. Thereafter, baseline sessions continued until the number of 
infusions obtained for a single session was within 20% of the initial baseline mean, at 
which point another test session occurred [12]. Baseline and test sessions alternated in 
this fashion until a naltrexone dose-effect curve was established. Naltrexone dose-effect 
curves were determined on 3 separate occasions, once prior to each test with MCAM. 
For the first determination of the naltrexone dose-effect curve, all monkeys received 
doses of 0.0032, 0.01, and 0.032 mg/kg. Doses of naltrexone in this range attenuate the 
reinforcing and ventilatory-depressant effects of heroin and other mu opioid receptor 
agonists in rhesus monkeys [e.g., 11,12]. For the second and third determinations, doses 
varied across monkeys, ranging from the largest dose that decreased infusions by less 
than 20% of the baseline to the smallest dose that decreased the number of infusions to 
fewer than 9. For each determination, the number of infusions obtained in baseline 
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sessions that preceded a test were averaged, and that mean value served as the baseline 
for that particular determination. 
Effects of acute MCAM administration. Effects of acute administration of 0.32 
mg/kg MCAM were established after the first naltrexone dose-effect curve was 
determined. Prior to the test, 0.032 mg/kg/infusion cocaine was available for self-
administration for at least 1 session to confirm that cocaine maintained levels of 
responding above saline in each monkey; this unit dose is at or near the peak of the 
cocaine self-administration dose-effect curve [e.g., 18,19], maintains the same level of 
responding as the unit dose of fentanyl, and was the same dose used in the previous 
study with MCAM [12]. Thereafter, 0.00032 mg/kg/infusion fentanyl was available until 
the number of infusions obtained in 1 session was within 20% of the baseline mean 
established prior to determination of the first naltrexone dose-effect curve. MCAM was 
given s.c. 60 min prior to the next session; the doses and pretreatment time were based 
on published data [12]. Saline (0.5 ml) was injected s.c. 60 min prior to the sessions 
conducted on the days immediately preceding and following the MCAM test session. 
Fentanyl was available during the session conducted on the day of the MCAM injection 
(Day 0) and for 2 days thereafter (Days 1 and 2), then cocaine was available for a single 
session (Day 3); fentanyl was available again for 3 sessions (Days 4, 5, and 6) followed 
by a single session in which cocaine was available (Day 7). This pattern continued, with 
cocaine substituted for fentanyl every fourth session, for at least 42 sessions (range: 42 
to 46) after MCAM administration. At that point, cocaine sessions were discontinued, the 
fentanyl self-administration baseline was re-established, and effects of naltrexone were 
determined a second time. Thereafter, 0.1 mg/kg MCAM was studied in the same manner 
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as the previous test. Cocaine was not tested in one monkey after this dose of MCAM 
because responding for fentanyl returned to baseline within 3 days of the injection. For 
the other monkeys, cocaine was substituted every fourth session, as before, with at least 
7 sessions (range: 7 to 15) conducted after MCAM administration, at which point cocaine 
sessions were discontinued, the fentanyl self-administration baseline was re-established, 
and the naltrexone dose-effect curve was determined a third time.  
Effects of repeated MCAM administration. Effects of repeated MCAM 
administration were tested following the third naltrexone dose-effect curve determination. 
A dose of 0.32 mg/kg MCAM was given 60 min prior to a fentanyl self-administration 
session and testing commenced, as before, with cocaine being substituted for fentanyl 
every fourth session. Four additional injections of 0.32 mg/kg MCAM were given 12 days 
apart (i.e., 12, 24, 36, and 48 days, respectively, after the initial MCAM injection). Fentanyl 
and cocaine sessions continued to alternate after the fifth MCAM injection for at least 38 
(range: 38-66) additional sessions.  
Plasma collection and analysis. Blood was collected in 2 groups of monkey (n=4 
per group) for analysis of MCAM concentrations in plasma. In one group of monkeys (4 
males), 0.32 mg/kg MCAM was administered s.c. on one occasion; blood was collected 
by acute puncture of the saphenous vein before and 15, 30, 45, 60, 120, and 360 min as 
well as 24 and 48 hr after the injection. The other group comprised the self-administration 
monkeys participating in the repeated MCAM administration experiment. Blood was 
collected immediately following the self-administration session on the day in which MCAM 
was given (Day 0) and on each of the following two days (Days 1 and 2); thus, sampling 
times were approximately 150 min (60 min pretreatment plus 90 min session), 1 day, and 
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2 days following each administration of 0.32 mg/kg MCAM. Samples were put in 3-ml 
EDTA tubes (Vacutainer; Becton, Dickson and Company, Franklin Lakes, NJ, USA) then 
immediately placed on ice and shielded from light. The tubes were centrifuged at 3000 × 
g for 10 minutes at 15ºC; plasma was collected in polypropylene tubes and stored at 
−80°C. 
HPLC/MS/MS system and analytical parameters. The high-pressure liquid 
chromatography (HPLC) system consisted of a Shimadzu CBM-20A controller (Shimadzu 
Scientific Instruments, Columbia, MD, USA), an LC-20AD pump with a FCV-20AL mixing 
chamber, a SIL-20A/HT autosampler, and an AB Sciex API 3200 tandem mass 
spectrometer with turbo ion spray (AB Sciex, Framingham, MA, USA). The analytical 
column was an Ace Excel 3 Super C18 (3 × 75 mm, 3 µ) purchased from MacMod 
(Chadds Ford, PA, USA) and maintained at 26°C during the chromatographic runs in a 
Shimadzu CTO-20A column oven. Mobile phase A was 0.1% formic acid dissolved in 
Milli-Q water, and mobile phase B was 0.1% formic acid dissolved in acetonitrile. The flow 
rate of the mobile phase was 0.4 ml/min. The gradient was: 0 to 1 min, 20%B; 1.1 to 6 
min, 20 to 99%B (linear); 6.1 to 8 min, 99%B; 8.1 to 10 min, 99 to 20%B (linear). The 
Q1/Q3 transition used to quantify MCAM was 485.5 m/z to 145.3 m/z. 
Milli-Q water was used for preparation of all solutions (Millipore, Billerica, MA, 
USA). MCAM super-stock solutions were prepared in methanol at a concentration of 1 
mg/ml and stored in aliquots at −80°C. Working stock solutions (1 or 10 µg/ml) of MCAM 
were prepared fresh each day from the super-stock solutions and used to spike the 
calibrator samples. To determine plasma concentrations of MCAM, 200 µl of calibrator 
and unknown plasma samples were mixed with 2 ml of a mobile phase B (0.1% formic 
12 
 
acid dissolved in acetonitrile). The samples were vortexed for 2 minutes, shaken for 30 
min, and then centrifuged at 3,200 g for 30 min at 23°C. Supernatants were dried to 
residue under a stream of nitrogen and residues were dissolved in 100 µl of 0.1% formic 
acid in water/acetonitrile (1:1). Then, 10 µl of the final samples were injected into the liquid 
chromatography–tandem mass spectrometry system. The peak areas of MCAM were 
compared to a linear regression of peak areas of spiked MCAM calibrator samples 
containing concentrations of 0, 1, 5, 10, 50, 100, 500, and 1,000 ng/ml of MCAM to 
calculate MCAM concentrations in unknown samples. The plasma concentrations of 
MCAM were expressed as ng/ml. 
Data analyses. The primary dependent measure for the self-administration 
experiments was the number of infusions obtained. Changes in body weight were also 
quantified by taking the difference between the weight each day and the weight 
immediately preceding an MCAM injection. Effects of dose, day, and determination 
(naltrexone only) as well as the interaction between factors were analyzed using a one- 
or two-way, repeated measures analysis of variance (ANOVA). The potency of naltrexone 
was quantified by estimating the ED50 using linear interpolation; changes in the potency 
of naltrexone were analyzed using log ED50 values and a one-way, repeated measures 
ANOVA. Plasma MCAM concentrations were plotted for individual monkeys as a function 
of time since MCAM administration. Half-life was estimated by calculating half of the 
maximum concentration observed in plasma (Cmax) and then interpolating between the 
two data points immediately surrounding that concentration, resulting in an estimate of 
the time from MCAM injection until plasma levels were reduced to half of the maximum. 
Half-life was the difference between the time obtained by interpolation and the observed 
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time to reach the maximum concentration (Tmax). Effects of day and injection number on 
plasma MCAM concentrations during repeated administration were analyzed using a two-
way, repeated-measures ANOVA. Post-hoc analyses were conducted using Dunnett’s 
test [20]. Statistical analyses were conducted using NCSS, version 10.0.13 (Kaysville, 
UT, USA).  
Drugs. The National Institute on Drug Abuse Drug Supply Program (Rockville, MD, 
USA) generously provided fentanyl hydrochloride, cocaine hydrochloride, and naltrexone 
hydrochloride. Methocinnamox (MCAM) was synthesized (Broadbear et al. 2000) and 
purchased (Syncom, Groningen, NL). Fentanyl, cocaine, and naltrexone were dissolved 
in 0.9% sterile saline, whereas MCAM was dissolved in 10% w/v 2-hydroxypropyl-β-
cyclodextrin. Fentanyl and cocaine were injected i.v. during self-administration sessions 
in a volume of 1 ml per 10 kg of body weight; naltrexone and MCAM were injected s.c. in 
a volume of approximately 0.32 ml per 10 kg of body weight. For pharmacokinetic studies, 
all reagents were purchased either from Sigma-Aldrich (St. Louis, MO, USA) or Fisher 
(Suwanee, GA, USA) and were HPLC grade or higher. Methocinnamox (MCAM) 
analytical standard was purchased from Syncom. 
RESULTS 
Effects of acute naltrexone administration. Monkeys obtained, on average, 
between 24.5 and 26.0 infusions of 0.00032 mg/kg/infusion fentanyl during baseline 
sessions and following saline pretreatment (data above “Baseline” and “S”, Fig. 1a and 
1b). During the first determination, naltrexone dose-dependently decreased responding 
for fentanyl, with 0.01 and 0.032 mg/kg significantly decreasing the number of infusions 
on the day of treatment compared to baseline; responding returned to baseline levels the 
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following day (Fig. 1a). A two-way ANOVA indicated a significant main effect of dose 
(F[2,35]=13.4, p<0.001) and day (F[2,35]=120.4, p<0.0001) as well as a significant dose-
by-day interaction (F[4,35]=21.1, p<0.0001). When tested later in the study, naltrexone 
again dose-dependently decreased responding for fentanyl (Fig. 1b), with effects lasting 
less than one day (data not shown). A two-way ANOVA on naltrexone dose-effect data 
indicated a main effect of dose of naltrexone (F[3,39]=51.7, p<0.0001), but no main effect 
of determination or dose-by-determination interaction. Mean (95% CI) ED50 values for 
naltrexone were 0.006 (0.005, 0.007), 0.007 (0.004, 0.013), and 0.006 (0.004, 0.009) 
mg/kg for the first, second, and third determinations, respectively; according to a one-way 
ANOVA, ED50 values did not differ significantly across determinations. 
Effects of acute MCAM administration. Before tests with MCAM, monkeys 
obtained, on average, between 21.5 and 23.3 infusions of fentanyl and between 20.3 and 
23.3 infusions of cocaine during baseline sessions (data above “B”, Figs. 2a, 2b, and 2c). 
When given acutely, MCAM decreased responding for fentanyl but not cocaine (squares 
and circles, respectively, Fig. 2a and 2b). Following a single administration of 0.1 mg/kg 
of MCAM, there was a significant main effect of day on the number of fentanyl 
(F[6,27]=11.6, p<0.0001), but not cocaine, infusions, with the number of fentanyl infusions 
being significantly lower than baseline for up to 2 days after MCAM administration (filled 
symbols, Fig. 2a). Following a single administration of 0.32 mg/kg MCAM, there was a 
significant main effect of day on the number of fentanyl (F[24,98]=6.32, p<0.0001), but 
not cocaine, infusions, with the number of fentanyl infusions being significantly lower than 
baseline for up to 13 days after MCAM administration (Fig. 2b). A two-way ANOVA on 
fentanyl infusions, including the treatment day as well as the first 6 days after MCAM 
15 
 
administration, indicated there was a main effect of dose of MCAM (F[1,55]=64.1, 
p<0.0001) and day (F[6,55]=12.3, p<0.0001) as well as a dose-by-day interaction 
(F[6,55]=7.2, p<0.0001). In contrast, for cocaine infusions, there was no main effect of 
dose of MCAM, no main effect of day, and no dose-by-day interaction. 
Effects of repeated MCAM administration. Repeated treatment with 0.32 mg/kg 
MCAM also decreased responding for fentanyl, but not cocaine, with effects lasting for 
the duration of treatment (Fig. 2c). There was a significant main effect of day on fentanyl 
(F[72,291]=3.85, p<0.0001), but not cocaine, infusions, with the number of fentanyl 
infusions remaining significantly lower than baseline consistently for up to 72 days during 
the course of repeated treatment. The number of fentanyl infusions returned to baseline 
levels at a slightly lower rate following repeated MCAM treatment, with infusions 
remaining significantly lower than baseline for up to 21 days following repeated 
administration and for up to 13 days following acute administration (compare the recovery 
of responding for fentanyl in Fig. 2b with data from Fig. 2c beginning with the last MCAM 
injection). A two-way ANOVA indicated a main effect of day (F[33,270]=13.1, p<0.0001), 
a main effect of treatment condition (F[1, 270]=7.9, p=0.005), as well as a day-by-
treatment interaction (F[33,270]=1.6, p=0.03).  
During repeated MCAM treatment, there was a modest but significant effect of day 
on body weight (F[96,387]=1.62, p=0.001; data not shown). Average gain in body weight 
was approximately 0.5 kg by the end of the experiment (Day 95); one monkey accounted 
for the increase almost entirely. There was no evidence of marked weight loss (≥ 0.5 kg) 
in any monkey following MCAM administration.  
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MCAM plasma levels. Following a single injection of 0.32 mg/kg MCAM s.c., 
plasma levels in individual monkeys reached peak concentrations, which ranged from 
10.6 to 26.0 ng/ml, 15-45 min after the injection (Fig. 3). These concentrations decreased 
with a half-life ranging from 13.7-199.8 min. In the self-administration group, mean MCAM 
plasma concentration ranged from, on average, 4.78 to 10.32 ng/ml immediately following 
the session (i.e., 150 minutes after administration) on the day 0.32 mg/kg MCAM was 
administered and was much lower the following days, ranging from 0.93 to 1.97 ng/ml 1 
day after injection and from 0.73 to 1.78 ng/ml 2 days after injection (Fig. 4). There was 
a main effect of day (F[3,62]=5.5, p=0.003) on plasma concentrations, but there was no 
main effect of test and no day-by-test interaction. MCAM plasma levels on the day of 
injection (days 0, 12, 24, 36, and 48) were significantly higher than control. One value for 
one monkey was excluded from the analysis (day 36, immediately following the 4th MCAM 
injection; Fig. 4) because that value (27.7 ng/ml) was more than 6 standard deviations 
higher than the mean plasma levels measured across the other four injections in the same 
monkey, which were 5.9, 5.2, 8.1, and 6.8 ng/ml.    
 
DISCUSSION 
Opioid abuse and overdose continue to be significant public health challenges 
despite the availability of effective medications, including methadone, buprenorphine, 
naltrexone, and naloxone. MCAM is a pseudoirreversible mu opioid receptor selective 
antagonist [8,9,10] that blocks the reinforcing and ventilatory-depressant effects of 
opioids in nonhuman primates, with effects of a single injection lasting days to weeks 
without any evidence of adverse effects [11,12]. Previous studies have demonstrated that 
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MCAM selectively reduces opioid self-administration, although it is important to know 
whether effects of MCAM are sustained over extended treatment and whether extended 
treatment with MCAM results in long-term changes that might have important 
consequences. This study evaluated MCAM for its capacity to reduce self-administration 
of the potent and high efficacy mu opioid receptor agonist fentanyl, characterized the 
effectiveness of repeated treatment with MCAM, and related behavioral effects of MCAM 
to its pharmacokinetic properties. Results of this study showed the following: 1) MCAM 
selectively decreased self-administration of fentanyl but not cocaine; 2) effects of a single 
injection of MCAM on fentanyl self-administration lasted much longer than those of 
naltrexone; 3) MCAM remained effective for over 2 months during a course of repeated, 
intermittent treatment; 4) recovery of responding for fentanyl after discontinuation of 
repeated MCAM administration was not markedly different from recovery following a 
single MCAM injection; and 5) MCAM remained effective despite very low concentrations 
in plasma.  
Effects of acute MCAM administration. When given acutely, MCAM and 
naltrexone decreased responding for fentanyl at doses that also decreased responding 
for heroin and reduced choice of remifentanil over food in rhesus monkeys [12]. Effects 
of naltrexone were relatively short-lived as responding returned to baseline levels the next 
day. In contrast, effects of a single injection of MCAM lasted much longer than those of 
naltrexone with the larger dose of MCAM decreasing fentanyl self-administration for up 
to 2 weeks. This duration of action is comparable to a previous study in which 0.32 mg/kg 
MCAM decreased heroin self-administration in rhesus monkeys for an average of 10 days 
following a single injection [12]. In comparison, the same dose of MCAM blocked the 
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ventilatory-depressant effects of very large doses of heroin, shifting the dose-effect curve 
rightward at least 10-fold, for at least 4 days, with the heroin dose-effect curve gradually 
returning to control over the course of 8 days [11]. 
Only one dose of fentanyl was tested in the current study. Given that the self-
administration dose-effect curves are usually biphasic (i.e., “inverted-U” shaped), 
decreased responding for a single dose could indicate a leftward or rightward shift in the 
dose-effect curve, with a leftward shift indicating enhancement of reinforcing effects and 
a rightward shift indicating attenuation. Based solely on the current data, it is not possible 
to determine whether MCAM enhanced or attenuated the reinforcing effects of fentanyl. 
However, in previous studies with rhesus monkeys, MCAM shifted dose-effect curves for 
choice of remifentanil over food [12] and the ventilatory-depressant effects of heroin [11] 
rightward in a dose-dependent fashion; thus, it appears likely that decreased self-
administration of fentanyl in the current study reflected attenuation, and not enhancement, 
of the reinforcing effects of fentanyl. MCAM did not alter self-administration of cocaine 
when it was available intermittently in the same monkeys during the same experiment. 
Selective attenuation of opioid, but not cocaine, self-administration by an opioid receptor 
antagonist is consistent with previous studies [12,21] and provides additional evidence 
that effects of MCAM on fentanyl self-administration were mediated through blockade of 
mu opioid receptors rather than through other mechanisms such as generalized 
suppression of operant behavior.  
Effects of repeated MCAM administration. Because successful management of 
OUD requires long-term, and usually repeated, treatment, this study also evaluated 
effects of repeated MCAM administration. MCAM continuously reduced fentanyl self-
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administration during a treatment regimen in which MCAM was administered once every 
12 days, with no evidence of a change in its effectiveness. The treatment interval was 
selected to use the longest inter-injection interval that would be predicted to produce a 
continuous reduction in self-administration of fentanyl, based on results obtained after 
acute dosing with MCAM. Although repeated bolus injections are not likely to be the 
treatment regimen when using MCAM to treat OUD, these data indicate that it will remain 
effective over an extended period. Moreover, these results set the stage for developing 
formulations that deliver very small doses of MCAM over an extended period of time, 
which could markedly improve treatment compliance by reducing the frequency of dosing 
required and ensuring exposure to the medication for a very long time.  
Like mu opioid receptor antagonists approved by the US Food and Drug 
Administration to treat OUD and opioid overdose (naltrexone and naloxone, respectively), 
MCAM would be devoid of many adverse effects associated with the agonists methadone 
and buprenorphine such as potential for abuse, ventilatory depression, and potentially 
adverse interactions with drugs that also decrease ventilation such as benzodiazepines 
and alcohol. Although MCAM has affinity for mu, kappa, and delta opioid receptors, it 
binds pseudoirreversibly only to mu opioid receptors [e.g., 8,10]. Thus, long-term 
blockade of kappa and delta opioid receptors is not a concern with MCAM, further 
indicating that MCAM would be an improvement over extended-release formulations of 
naltrexone (i.e. Vivitrol), which would cause sustained blockade of all three types of opioid 
receptors. Moreover, MCAM did not decrease responding for food or alter heart rate, 
blood pressure, or body temperature up to a dose of 3.2 mg/kg, 10-fold larger than the 
dose that markedly decreases opioid self-administration [12], suggesting a low risk for 
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adverse effects. Although irreversible mu opioid receptor antagonists such as β-
funaltrexamine can disrupt feeding behavior [e.g., 22], repeated treatment with MCAM at 
a frequency that continuously decreased fentanyl self-administration for more than 2 
months did not result in significant weight loss or produce other overt signs of disrupted 
feeding or drinking in monkeys.  
Long-term blockade of mu opioid receptors might be expected to perturb the 
endogenous opioid system, which could manifest as alterations in effects of drugs acting 
at opioid receptors. Effects of naltrexone were determined between MCAM tests to probe 
for such effects, and the potency of naltrexone to decrease opioid self-administration 
determined immediately before and following recovery of responding after MCAM 
treatment was not significantly different [current study; 12]. Naltrexone was not tested 
after repeated MCAM in the current experiment; however, recovery of responding for 
fentanyl could be considered a surrogate measure of the return of opioid system 
sensitivity [23,24]. Responding in all monkeys returned to baseline on generally the same 
timeline following acute and repeated treatment with MCAM, suggesting there was no 
marked acceleration or delay in opioid system normalization. The lengthy recovery in 
fentanyl self-administration following acute and repeated MCAM treatment suggests that 
patients would remain protected against abuse-related effects of opioids for days or even 
weeks following discontinuation of MCAM treatment. Moreover, given that the duration of 
protection against opioid-induced ventilatory depression parallels effects on opioid self-
administration [11,12], patients would also remain protected against opioid overdose.  
MCAM pharmacodynamics and pharmacokinetics. The long duration of action 
of MCAM is thought to be due, at least in part, to irreversible binding to mu opioid 
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receptors. That is, MCAM binds to but does not dissociate from the receptor, rendering 
the receptor unavailable to other ligands; recovery of function is thus related to the 
restoration of functional receptors. At sufficient levels of receptor occupancy, irreversible 
binding of mu opioid receptors by MCAM would be expected to provide sustained and 
insurmountable protection against the reinforcing effects that contribute to abuse and the 
respiratory-depressant effects that lead to overdose and death. However, whether an 
antagonist such as MCAM will provide insurmountable protection depends on several 
factors including the number of receptors occupied by the antagonist, the efficacy 
requirement of the mu opioid receptor agonist-mediated effect, and the intrinsic efficacy 
of the agonist [e.g., 25]. Therefore, it is possible that, at some doses, MCAM will provide 
greater protection against adverse effects of opioids with moderate efficacy than against 
adverse effects of opioids with higher efficacy. Characterizing the scope and magnitude 
of the type of protection that MCAM provides is an ongoing effort. Nevertheless, studies 
to date indicate that MCAM provides substantial and long-lasting protection against the 
reinforcing and ventilatory-depressant effects of opioids with high efficacy such as heroin 
and fentanyl [current study, 11,12]. 
To date, there is no direct evidence of pseudoirreversible binding of MCAM in vivo. 
It is possible that MCAM remains in circulation providing continuous blockade of mu 
opioid receptors. Slow clearance and/or tissue sequestration might help to sustain high 
levels of circulating MCAM long after its administration. Such effects would be similar to 
those of repeated or continuous infusion of competitive, reversible antagonists such as 
naltrexone on opioid self-administration [e.g., 26]. In the current study, the 
pharmacokinetic profile of MCAM was examined to determine whether sustained plasma 
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concentrations account for its long duration of action. Data appeared to represent 
biphasic elimination, although there were too few data points to discriminate between 
one- and two-phase models and variability was unexpectedly high when the data were fit 
to the simpler (one-phase) model. Nevertheless, results obtained in individual monkeys 
show that MCAM remained effective even when plasma concentrations were very low, 
supporting the view that pharmacodynamic factors (i.e., pseudoirreversible binding to mu 
opioid receptors) play a significant role in its long-lasting effects, although, at this time a 
role for long-term sequestration in the central nervous system, as is the case with the 
long-acting kappa opioid receptor antagonist nor-binaltorphamine [27], cannot be ruled 
out. Moreover, plasma MCAM concentration obtained on the day of the injection did not 
differ systematically across repeated administrations suggesting that MCAM did not 
accumulate in the blood or alter its own pharmacokinetic profile when injections were 
separated by 12 days.  
CONCLUSIONS 
These results confirm and extend previous studies, demonstrating that MCAM 
selectively reduces opioid self-administration for a very long time after a single 
administration and remains effective with repeated administration. The long duration of 
action of MCAM is likely due, at least in part, to pseudoirreversible binding to mu opioid 
receptors, suggesting it can insurmountably block the abuse- and overdose-related 
effects of opioids, which, in turn, would markedly reduce the risk of overdose and death. 
Such a long duration of antagonist action might be preferable for treating OUD in some 
patients for whom access to adequate health care is limited. Moreover, treatment 
compliance would likely increase in so far as binding of MCAM to mu opioid receptors 
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cannot easily be reversed, for example, by removing an implant. Taken together with 
previous studies, these data indicate that MCAM could be an effective, long-acting 
treatment for OUD and overdose which would be a desperately needed addition to the 
armamentarium currently available to combat the opioid crisis.   
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FIGURE LEGENDS 
Fig. 1 Time- and dose-dependent effects of naltrexone on fentanyl self-
administration. a Time course of effects of naltrexone on fentanyl self-administration 
(n=4). The number of fentanyl infusions per session is plotted across three consecutive 
sessions: immediately preceding a test (“Baseline”), 15 min after an injection of 
naltrexone (“Treatment”), and 1 day after an injection of naltrexone (“1 day after”). Each 
symbol indicates a test with a different dose of naltrexone. The shaded region shows the 
range across baseline sessions for individual monkeys, and the arrow and vertical dashed 
line indicate the day on which naltrexone was administered. b Naltrexone dose-effect 
curves plotted for each of three determinations during the course of the study (n=4, except 
as indicated below). The mean number of fentanyl infusions is plotted for pretreatment 
with saline (above S) and increasing doses of naltrexone. All monkeys were tested with 
0.0032, 0.01, ad 0.032 mg/kg for the first determination. The range of doses tested varied 
across monkeys for the 2nd and 3rd determinations depending on effects of naltrexone, as 
follows: 2nd determination, 0.001 mg/kg (n=1) and 0.032 mg/kg (n=2); 3rd determination, 
0.001 mg/kg (n=1) and 0.032 mg/kg (n=1). For both panels, symbols represent the mean 
(± 1 SEM); filled symbols indicate data that are significantly different from baseline (a) or 
saline (b) according to a Dunnett’s test (p<0.05).  
Fig. 2 Effects of acute or repeated treatment with MCAM on self-
administration of fentanyl or cocaine. Panels a and b show effects of a single injection 
of 0.1 and 0.32 mg/kg MCAM, respectively; panel c shows effects of repeated injections 
of 0.32 mg/kg MCAM, with injections separated by 12 days. For all panels, n=4 except for 
cocaine data in panel a which is n=3 (see “Effects of acute MCAM administration” for 
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more information). The number of infusions is plotted across consecutive days; symbols 
above “B” indicate data from the sessions preceding MCAM injection, whereas symbols 
above “T” indicate data from the session on the day of treatment (i.e., 60 min after MCAM 
injection). Symbols represent the mean (± 1 SEM); filled symbols indicate data that are 
significantly different from baseline according to a Dunnett’s test (p<0.05). The shaded 
region shows the range of the baseline sessions across individual monkeys, and the 
arrows and vertical dashed lines indicate the days on which MCAM was administered. 
 Fig. 3 Plasma concentration of MCAM following acute MCAM administration. 
Plasma MCAM concentration in ng/ml is plotted as a function of time since MCAM 
administration. Each symbol shows data from individual monkeys. The table inset shows 
pk parameters derived for each monkey. Tmax is the observed time to reach the maximum 
concentration; Cmax is the maximum concentration observed in plasma; and T1/2 is an 
estimate of the time from MCAM injection until plasma levels were reduced to half of the 
maximum. One monkey was excluded from the 360 min time point and another from the 
2880 min time point because a sample was not collected.  
 Fig. 4 Plasma concentration of MCAM following repeated MCAM 
administration. Plasma was collected immediately following the self-administration 
session on the day in which MCAM was given and on each of the following two days. 
Each triad of data points shows plasma MCAM concentration in ng/ml for an MCAM 
injection. Numbers along the abscissa indicate days since the first MCAM injection of the 
test; the data point above “C” indicates concentration in plasma collected before the 
experiment and prior to the first MCAM administration. Each data point represents the 
mean (± 1 SEM) for four monkeys, except for day 25, when blood was not collected from 
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one monkey, and for day 36, when an outlier was excluded (see Results for details). Filled 
symbols indicate means that are statistically different from baseline (data point above “C”) 
according to a Dunnett’s test (p<0.05).  
